ALNY News 56.42 07/15/2014 04:30:31 Alnylam Pharmaceuticals
Post# of 273331
Posted On: 07/15/2014 5:30:32 AM
Alnylam Pharmaceuticals (ALNY) 56.42 $ALNY
What RXi Pharmaceuticals' Move to the Russell Microcap Index Means
ACCESSWIRE - Wed Jul 09, 8:48AM CDT
WHITEFISH, MT / July 9, 2014 / RXi Pharmaceuticals Corp. (NASDAQ: RXII), a biotechnology company focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, recently began trading on the Russell Microcap index on June 27, 2014. Membership on the index remains for one year and is based on market cap and style attributes.
Patient Enrollments, Board Appointments, Acquisitions, and Technical Updates - Analyst Notes on Questcor, Synta, Clovis, Alnylam and Intrexon
PR Newswire - Tue Jul 08, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Clovis Oncology, Inc. (NASDAQ: CLVS), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Intrexon Corporation (NYSE: XON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4522-100free.
Growth and Dividends: Europe's Best Pharma Stock
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jul 07, 4:00PM CDT
This stock is making smart investments in biotech -- and not just through partnerships, but through actual equity investments in biotechs like Regeneron and Alnylam Pharmaceuticals . It's a smart play for income investors (3.5% dividend yield)...
Alnylam to Host "RNAi Roundtable" Webcast Series
Business Wire - Mon Jul 07, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast a series of online "RNAi Roundtables" during July and August. Alnylam scientists and key clinical collaborators will review recent progress from several of the "Alnylam 5x15" programs and discuss the related disease areas. Each event will be webcast live on the Investors section of the company's website, www.alnylam.com. An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.
Alnylam Elects Amy Schulman to its Board of Directors
Business Wire - Wed Jul 02, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the election of Amy W. Schulman to its Board of Directors. Ms. Schulman is the former Executive Vice President and General Counsel of Pfizer Inc., and served as the Business Unit Lead for Pfizer's Consumer Healthcare business. She currently serves on the faculty of Harvard Business School as a Senior Lecturer.
Alnylam Added to Russell 1000 Index as a Member of the Large-Cap Segment of the U.S. Equity Universe
Business Wire - Mon Jun 30, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has been added to the Russell 1000 Index, effective June 27, 2014. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe. It is a subset of the Russell 3000 Index and includes approximately 1000 of the largest securities based on a combination of their market cap and current index membership.
Senior Notes Offerings, Study Findings, Recognitions, Accreditations, and Collaborations - Analyst Notes on Tenet, Hologic, PAREXEL, Centene and Alnylam
PR Newswire - Mon Jun 30, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Tenet Healthcare Corp (NYSE: THC), Hologic, Inc. (NASDAQ: HOLX), PAREXEL International Corporation (NASDAQ: PRXL), Centene Corp (NYSE: CNC) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4251-100free.
Look for Shares of Alnylam Pharmaceuticals to Potentially Rebound after Yesterday's 3.73% Sell Off
Comtex SmarTrend(R) - Thu Jun 26, 5:38PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $64.08 to a high of $67.49. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $65.08 on volume of 821,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Alnylam Pharmaceuticals Up 17.8% Since SmarTrend Uptrend Call (ALNY)
Comtex SmarTrend(R) - Tue Jun 24, 11:04AM CDT
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on May 13th, 2014 at $58.19. In approximately 1 month, Alnylam Pharmaceuticals has returned 17.78% as of today's recent price of $68.53.
Alnylam-TAP Collaborate for AAT Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 3:45PM CDT
Alnylam Pharmaceuticals (ALNY) inked a collaboration deal with TAP for the continued development of ALN-AAT.
Alnylam and The Alpha-1 Project (TAP) Form Collaboration for Advancement of ALN-AAT, an RNAi Therapeutic in Development for the Treatment of Alpha-1 Antitrypsin (AAT) Deficiency-Associated Liver Disease
Business Wire - Thu Jun 19, 7:58AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and The Alpha-1 Project (TAP), the venture philanthropy subsidiary of the Alpha-1 Foundation, announced today that they have entered into a collaboration agreement for the continued advancement of ALN-AAT, a subcutaneously administrated RNAi therapeutic in development for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease. TAP's mission is to work with patients, academia, pharmaceutical and biotech companies, and public health organizations in the pursuit of cures and therapies for chronic obstructive pulmonary disease (COPD) and liver disease caused by AAT deficiency. TAP is partially funding research activities for ALN-AAT. Detailed financial terms of the research agreement were not disclosed. Alnylam remains on track to file an investigational new drug (IND) application for this program in mid-2015.
Alnylam to Webcast Presentation at 9th Annual JMP Securities Healthcare Conference
Business Wire - Tue Jun 17, 3:13PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 9th Annual JMP Securities Healthcare Conference on Tuesday, June 24, 2014 at 10:30 a.m. ET at the Westin New York Grand Central in New York City.
Alnylam Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.36%
Comtex SmarTrend(R) - Mon Jun 16, 5:54PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $67.99 to a high of $71.40. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $69.54 on volume of 686,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Alnylam Announces United States Patent and Trademark Office (USPTO) Issues Patent Covering RNAi Therapeutics for the Treatment of Hepatitis B Virus (HBV) Infection
Business Wire - Thu Jun 12, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a new patent (U.S. patent no. 8,618,277, or "'277 patent"
in the company's McSwiggen patent estate. The McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics needed to achieve "drug-like" properties in siRNA, the molecules that mediate RNAi. Specifically, the '277 patent includes claims that the company believes are critical for the development of RNAi therapeutics for the treatment of hepatitis B virus (HBV) infection. This patent is held exclusively by Alnylam and is not licensed to any third parties. The McSwiggen patent estate comprises a core component of Alnylam's overall intellectual property (IP) estate for the advancement of RNAi therapeutics, and was recently obtained through the company's acquisition of Sirna Therapeutics from Merck.
Trial Results, Patient Enrollment, and Strategic Collaborations - Analyst Notes on Alnylam, Celldex, Keryx, Spectrum and MacroGenics
PR Newswire - Thu Jun 12, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and MacroGenics, Inc. (NASDAQ: MGNX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3634-100free.
Uptrend Call Working As Alnylam Pharmaceuticals Stock Rises 15.1% (ALNY)
Comtex SmarTrend(R) - Tue Jun 10, 9:10AM CDT
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on May 13th, 2014 at $58.19. In approximately 4 weeks, Alnylam Pharmaceuticals has returned 15.13% as of today's recent price of $66.99.
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 7.53% Rise
Comtex SmarTrend(R) - Mon Jun 09, 5:04PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $61.26 to a high of $66.86. Yesterday, the shares gained 7.5%, which took the trading range above the 3-day high of $61.38 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
RXi Pharma Advances sd-rxRNA Platform with Key Patent
ACCESSWIRE - Mon Jun 09, 9:04AM CDT
WHITEFISH, MT / June 9th , 2014 / RNA therapeutics have been growing in popularity over the past couple years with the FDA approval of ISIS Pharmaceuticals' (NASDAQ: ISIS) and Sanofi SA's (NYSE: SNY) Kynamro(R) as the first antisense drug to reach the market and Alnylam Pharmaceuticals' (NASDAQ: ALNY) successes in late-stage clinical trials utilizing RNA interference ("RNAi" in its so-called 5×15 clinical pipeline.
Alnylam Presents New Pre-Clinical Data with Development Candidate for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases
Business Wire - Mon Jun 09, 7:01AM CDT
--- RNAi-Mediated Knockdown of C5 Shown to be as Effective as Anti-C5 Monoclonal Antibody in Reducing Clinical Disease Activity in Mouse Arthritis Model -
What RXi Pharmaceuticals' Move to the Russell Microcap Index Means
ACCESSWIRE - Wed Jul 09, 8:48AM CDT
WHITEFISH, MT / July 9, 2014 / RXi Pharmaceuticals Corp. (NASDAQ: RXII), a biotechnology company focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, recently began trading on the Russell Microcap index on June 27, 2014. Membership on the index remains for one year and is based on market cap and style attributes.
Patient Enrollments, Board Appointments, Acquisitions, and Technical Updates - Analyst Notes on Questcor, Synta, Clovis, Alnylam and Intrexon
PR Newswire - Tue Jul 08, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Clovis Oncology, Inc. (NASDAQ: CLVS), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Intrexon Corporation (NYSE: XON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4522-100free.
Growth and Dividends: Europe's Best Pharma Stock
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jul 07, 4:00PM CDT
This stock is making smart investments in biotech -- and not just through partnerships, but through actual equity investments in biotechs like Regeneron and Alnylam Pharmaceuticals . It's a smart play for income investors (3.5% dividend yield)...
Alnylam to Host "RNAi Roundtable" Webcast Series
Business Wire - Mon Jul 07, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast a series of online "RNAi Roundtables" during July and August. Alnylam scientists and key clinical collaborators will review recent progress from several of the "Alnylam 5x15" programs and discuss the related disease areas. Each event will be webcast live on the Investors section of the company's website, www.alnylam.com. An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.
Alnylam Elects Amy Schulman to its Board of Directors
Business Wire - Wed Jul 02, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the election of Amy W. Schulman to its Board of Directors. Ms. Schulman is the former Executive Vice President and General Counsel of Pfizer Inc., and served as the Business Unit Lead for Pfizer's Consumer Healthcare business. She currently serves on the faculty of Harvard Business School as a Senior Lecturer.
Alnylam Added to Russell 1000 Index as a Member of the Large-Cap Segment of the U.S. Equity Universe
Business Wire - Mon Jun 30, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has been added to the Russell 1000 Index, effective June 27, 2014. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe. It is a subset of the Russell 3000 Index and includes approximately 1000 of the largest securities based on a combination of their market cap and current index membership.
Senior Notes Offerings, Study Findings, Recognitions, Accreditations, and Collaborations - Analyst Notes on Tenet, Hologic, PAREXEL, Centene and Alnylam
PR Newswire - Mon Jun 30, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Tenet Healthcare Corp (NYSE: THC), Hologic, Inc. (NASDAQ: HOLX), PAREXEL International Corporation (NASDAQ: PRXL), Centene Corp (NYSE: CNC) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4251-100free.
Look for Shares of Alnylam Pharmaceuticals to Potentially Rebound after Yesterday's 3.73% Sell Off
Comtex SmarTrend(R) - Thu Jun 26, 5:38PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $64.08 to a high of $67.49. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $65.08 on volume of 821,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Alnylam Pharmaceuticals Up 17.8% Since SmarTrend Uptrend Call (ALNY)
Comtex SmarTrend(R) - Tue Jun 24, 11:04AM CDT
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on May 13th, 2014 at $58.19. In approximately 1 month, Alnylam Pharmaceuticals has returned 17.78% as of today's recent price of $68.53.
Alnylam-TAP Collaborate for AAT Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 3:45PM CDT
Alnylam Pharmaceuticals (ALNY) inked a collaboration deal with TAP for the continued development of ALN-AAT.
Alnylam and The Alpha-1 Project (TAP) Form Collaboration for Advancement of ALN-AAT, an RNAi Therapeutic in Development for the Treatment of Alpha-1 Antitrypsin (AAT) Deficiency-Associated Liver Disease
Business Wire - Thu Jun 19, 7:58AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and The Alpha-1 Project (TAP), the venture philanthropy subsidiary of the Alpha-1 Foundation, announced today that they have entered into a collaboration agreement for the continued advancement of ALN-AAT, a subcutaneously administrated RNAi therapeutic in development for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease. TAP's mission is to work with patients, academia, pharmaceutical and biotech companies, and public health organizations in the pursuit of cures and therapies for chronic obstructive pulmonary disease (COPD) and liver disease caused by AAT deficiency. TAP is partially funding research activities for ALN-AAT. Detailed financial terms of the research agreement were not disclosed. Alnylam remains on track to file an investigational new drug (IND) application for this program in mid-2015.
Alnylam to Webcast Presentation at 9th Annual JMP Securities Healthcare Conference
Business Wire - Tue Jun 17, 3:13PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 9th Annual JMP Securities Healthcare Conference on Tuesday, June 24, 2014 at 10:30 a.m. ET at the Westin New York Grand Central in New York City.
Alnylam Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.36%
Comtex SmarTrend(R) - Mon Jun 16, 5:54PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $67.99 to a high of $71.40. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $69.54 on volume of 686,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Alnylam Announces United States Patent and Trademark Office (USPTO) Issues Patent Covering RNAi Therapeutics for the Treatment of Hepatitis B Virus (HBV) Infection
Business Wire - Thu Jun 12, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a new patent (U.S. patent no. 8,618,277, or "'277 patent"
in the company's McSwiggen patent estate. The McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics needed to achieve "drug-like" properties in siRNA, the molecules that mediate RNAi. Specifically, the '277 patent includes claims that the company believes are critical for the development of RNAi therapeutics for the treatment of hepatitis B virus (HBV) infection. This patent is held exclusively by Alnylam and is not licensed to any third parties. The McSwiggen patent estate comprises a core component of Alnylam's overall intellectual property (IP) estate for the advancement of RNAi therapeutics, and was recently obtained through the company's acquisition of Sirna Therapeutics from Merck. Trial Results, Patient Enrollment, and Strategic Collaborations - Analyst Notes on Alnylam, Celldex, Keryx, Spectrum and MacroGenics
PR Newswire - Thu Jun 12, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and MacroGenics, Inc. (NASDAQ: MGNX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3634-100free.
Uptrend Call Working As Alnylam Pharmaceuticals Stock Rises 15.1% (ALNY)
Comtex SmarTrend(R) - Tue Jun 10, 9:10AM CDT
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on May 13th, 2014 at $58.19. In approximately 4 weeks, Alnylam Pharmaceuticals has returned 15.13% as of today's recent price of $66.99.
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 7.53% Rise
Comtex SmarTrend(R) - Mon Jun 09, 5:04PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $61.26 to a high of $66.86. Yesterday, the shares gained 7.5%, which took the trading range above the 3-day high of $61.38 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
RXi Pharma Advances sd-rxRNA Platform with Key Patent
ACCESSWIRE - Mon Jun 09, 9:04AM CDT
WHITEFISH, MT / June 9th , 2014 / RNA therapeutics have been growing in popularity over the past couple years with the FDA approval of ISIS Pharmaceuticals' (NASDAQ: ISIS) and Sanofi SA's (NYSE: SNY) Kynamro(R) as the first antisense drug to reach the market and Alnylam Pharmaceuticals' (NASDAQ: ALNY) successes in late-stage clinical trials utilizing RNA interference ("RNAi"
in its so-called 5×15 clinical pipeline. Alnylam Presents New Pre-Clinical Data with Development Candidate for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases
Business Wire - Mon Jun 09, 7:01AM CDT
--- RNAi-Mediated Knockdown of C5 Shown to be as Effective as Anti-C5 Monoclonal Antibody in Reducing Clinical Disease Activity in Mouse Arthritis Model -
(0)
(0)